MaxCyte and Kamau Therapeutics sign platform license agreement
Pharmaceutical Technology
SEPTEMBER 17, 2024
MaxCyte has entered into a license agreement with Kamau Therapeutics, a clinical-stage company focused on stem cell therapy gene correction.
Licensing Related Topics 
Clearmind licenses psychedelic compounds for mental disorders
Pharmaceutical Technology
APRIL 18, 2024
Clearmind Medicine has entered into a licensing agreement with Yissum to develop Generation 3.0 psychedelic compounds for mental disorders.
Licensing 
246
246 Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Sanofi signs radioligand therapy licensing deal for rare cancers
Pharmaceutical Technology
SEPTEMBER 13, 2024
Sanofi has signed a licensing agreement with RadioMedix and Orano Med to advance a radioligand therapy, AlphaMedix.
Licensing 130
130 
Almirall licenses IL-21 antibody from Novo Nordisk
Pharmaceutical Technology
FEBRUARY 19, 2024
Almirall has signed a licensing agreement for the acquisition of worldwide rights to Novo Nordisk’s IL21-hindering antibody NN-8828.
Licensing 241
241 
Anocca signs licensing deal for EmendoBio’s gene-editing tech
Pharmaceutical Technology
MARCH 15, 2024
Anocca has entered a licensing agreement with EmendoBio for the use of the latter’s OMNI-A4 nuclease, a gene editing technology.
Gene Editing 244
244 
Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune
Bio Pharma Dive
MAY 13, 2024
The deal — worth $100 million up front and potentially billions more later on — gives Takeda an exclusive option to license an Alzheimer’s vaccine and other “active immunotherapies.”
Licensing 204
204 
Specialised Therapeutics partners with Treeway to license ALS drug
Pharmaceutical Technology
AUGUST 28, 2023
Specialised Therapeutics has entered into a licensing agreement with Treeway for TW001, designed for treating amyotrophic lateral sclerosis.
Licensing 246
246 
J&J jumps on ADC train, signs $1.7bn licensing deal with LegoChem
Pharmaceutical Technology
DECEMBER 28, 2023
J&J has acquired a global license for South Korean LegoChem’s ADC for $100m upfront along with milestone-based payments and tiered royalties.
Licensing 245
245 
Benefits of Drug Patent Licensing Agreements
Drug Patent Watch
JULY 30, 2024
The Power of Patent Licensing: Unlocking Innovation and Access to Medicines Patent licensing agreements have become a crucial tool in the pharmaceutical industry, allowing companies to collaborate and…
Licensing 105
105 
Licensing agreements for innovator GLP1R drugs weigh in with over $6.2bn in 2024
Pharmaceutical Technology
AUGUST 21, 2024
Innovator drugs targeting GLP1R witnessed a 595% increase in total licensing agreement deal value from 2019 to 2024 YTD.
Licensing 130
130 
Advanz wins stay on EU revocation of Ocaliva license
pharmaphorum
SEPTEMBER 5, 2024
EU General Court suspends decision to revoke the license for Advanz Pharma's primary biliary cholangitis drug Ocaliva.
Licensing 116
116 
TN govt appoints M N Sridhar as state licensing authority & controlling authority for DC department
AuroBlog - Aurous Healthcare Clinical Trials blog
JUNE 26, 2024
The Tamil Nadu government has appointed the incumbent controlling authority (CA) of the drugs control administration, M N Sridhar, as state licensing and controlling authority (SLA and CA) for the department of drugs control from June 18 onwards.
Licensing 162
162 
Enveric Biosciences to out-license psilocin prodrug to MindBio
Pharmaceutical Technology
MAY 15, 2024
Enveric Biosciences has entered a non-binding term sheet with MindBio Therapeutics to out-license a class of psilocin prodrugs.
Licensing 130
130 
Genezen to license CSL’s lentiviral vector production system
Pharmaceutical Technology
FEBRUARY 21, 2024
Contract development and manufacturing organisation Genezen has announced plans to license CSL’s Cytegrity lentivirus production system.
Licensing 130
130 
Roche licenses Sangamo’s technology for another shot at Alzheimer’s drugs
Bio Pharma Dive
AUGUST 6, 2024
Through a new deal, Roche has exclusive rights to Sangamo molecules designed to repress the gene that makes “tau,” a protein many scientists view as a main driver of Alzheimer’s.
Licensing 334
334 
Sanofi signs $1.2bn licensing agreement for Novavax’s Covid-19 vaccine
Pharmaceutical Technology
MAY 10, 2024
Sanofi has signed a $1.2bn licensing agreement with Novavax to co-commercialise its stand-alone adjuvanted Covid-19 vaccine.
Licensing 130
130 
Ayush Ministry to amend D&C Rules mandating cGMP for homoeopathic drug manufacturing license
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 13, 2024
The Union Ministry of Ayush will soon amend the Drugs and Cosmetic Rules, 1945 to mandate good manufacturing practices for Homoeopathy drug manufacturing, stipulating procedures for loan licensing in the system of Homoeopathy and specifying timelines for issuance of license, among others.
Licensing 160
160 
Cristália signs licensing deal for Formosa’s APP13007
Pharmaceutical Technology
JANUARY 29, 2024
Cristália has signed an agreement to license exclusive rights to market Formosa Pharmaceuticals’ APP13007 in Brazil.
Licensing 130
130 
CDSCO reminds medical device firms to pay retention fee to continue holding licenses & certificates
AuroBlog - Aurous Healthcare Clinical Trials blog
MAY 23, 2024
The Central Drugs Standard Control Organisation (CDSCO) has requested all stakeholders in the medical devices sector to deposit the requisite fee for retention of license or registration certificate under the Medical Devices Rules (MDR), 2017, well before the stipulated timeline in order to avoid cancellation of the approvals.The drug regulator, in (..)
Licensing 156
156 
Licensing regime posing challenge to micro and small medical devices industry: SMTA
AuroBlog - Aurous Healthcare Clinical Trials blog
JANUARY 25, 2024
The Central government’s actions to mandate licensing of all medical devices is posing a challenge to the industry, especially the micro and small enterprises in the sector, says the Surgical Manufacturers and Traders Association (SMTA), the pan India organisation of manufacturers and traders of surgical equipment for healthcare services providers (..)
Licensing 177
177 
Astria to license Ichnos Sciences’ OX40 portfolio
Pharmaceutical Technology
OCTOBER 12, 2023
Astria Therapeutics has signed a global exclusive agreement to license Ichnos Sciences’ OX40 portfolio for treating atopic dermatitis (AD).
Licensing 130
130 
AbbVie licenses OSE’s chronic inflammation therapy for $48m upfront
Pharmaceutical Technology
FEBRUARY 28, 2024
AbbVie will pay $48m in upfront costs and up to $665m in milestone payments to license OSE’s monoclonal antibody OSE-230.
Licensing 130
130 
Adcendo licenses Multitude anti-TF ADC in $1bn+ deal
pharmaphorum
AUGUST 20, 2024
Danish biotech Adcendo has accelerated its progression to a clinical-stage biotech by licensing an antibody-drug conjugate (ADC) from China's Multitude Therapeutics with potential in various forms of cancer.Copenhagen-based Adcendo is paying what is rumours to be tens of millions of dollars in upfront fees for rights to Multitude's anti-tissue factor (..)
Licensing 104
104 
IMIDomics to license TNAX’s drug candidate for IMIDs
Pharmaceutical Technology
SEPTEMBER 7, 2023
IMIDomics has entered an agreement to license TNAX Biopharma’s IMB1001 to treat immune-mediated inflammatory diseases (IMIDs).
Licensing 147
147 
Specialised Therapeutics licenses CanariaBio’s ovarian cancer antibody
Pharmaceutical Technology
OCTOBER 13, 2023
Specialised Therapeutics has entered an agreement to license Korea-based CanariaBio’s oregovomab for treating ovarian cancer.
Licensing 130
130 
AbbVie licenses FutureGen IBD drug in $1.7bn deal
pharmaphorum
JUNE 13, 2024
AbbVie agrees $1.7bn deal with China's FutureGen to license an anti-TL1A inflammatory bowel disease therapy still in preclinical development
Licensing 114
114 
Coeptis licenses Deverra Therapeutics’ clinical stage assets
Pharmaceutical Technology
AUGUST 18, 2023
Coeptis Therapeutics has exclusively licensed allogeneic immuno-oncology platform and clinical stage assets from Deverra Therapeutics.
Licensing 130
130 
Vertex licenses Editas’ gene editing technology in $100m deal
Pharmaceutical Technology
DECEMBER 14, 2023
The payment, which encompasses newly approved Casgevy, is the latest deal in a long line of CRISPR licensing twists and turns.
Gene Editing 130
130 
Investors put $400M into biotech licensing obesity drugs from China
Bio Pharma Dive
MAY 16, 2024
The biotech, tentatively named Hercules CM Newco, has rights to three incretin drugs discovered by Jiangsu Hengrui Pharmaceuticals, two of which are in clinical testing.
Licensing 356
356 
CRISPR drug licensing deals secure $21bn in top three therapy areas over five years
Pharmaceutical Technology
MARCH 28, 2024
Licensing agreements for innovator drugs utilising clustered regularly interspaced short palindromic repeats (CRISPR) technologies saw oncology, immunology, and central nervous system as the top three therapy areas by total deal value with a combined $21bn over the past five years.
Licensing 130
130 
Sanofi bows to FTC demands and ends Maze licensing deal
Pharmaceutical Technology
DECEMBER 12, 2023
The license of Maze’s GYS1 program, including MZE-001, was the subject of FTC opposition, leading to Sanofi terminating the agreement
Licensing 130
130 
Biogen licenses a stroke drug from Japanese drugmaker TMS
Bio Pharma Dive
MAY 12, 2021
The drug, which Biogen had an option to license, is one of two in the biotech's pipeline for a condition that has had few new treatments developed.
Licensing 246
246 
Reset Pharma partners with Filament to license psilocybin drug
Pharmaceutical Technology
SEPTEMBER 1, 2023
Reset Pharma has entered a licensing agreement with Filament for psilocybin drug PEX010, designed for treating demoralisation syndrome.
Licensing 130
130 
NHS trust bids to take license for abandoned gene therapy
pharmaphorum
APRIL 9, 2024
Great Ormond Street Hospital is applying for the license to a gene therapy for rare disease ADA-SCID that was abandoned by a biotech developer on commercial grounds.
Gene Therapy 119
119 
Kite and Daiichi Sankyo update cell therapy licensing agreement
Pharmaceutical Technology
DECEMBER 8, 2022
The post Kite and Daiichi Sankyo update cell therapy licensing agreement appeared first on Pharmaceutical Technology. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Licensing 305
305 
Alteogen signs global license deal with Sandoz
Pharmaceutical Technology
JANUARY 2, 2023
South Korean biotechnology company Alteogen has signed an exclusive license agreement with Swiss company Sandoz to develop and market biosimilar products that are enabled by the former’s Hybrozyme technology. Additionally, the company will have an option to license Alteogen’s Hybrozyme technology for two more products.
Licensing 130
130 
Shorla enters deal to license chemotherapy drug in US
Pharmaceutical Technology
JULY 7, 2023
Shorla Oncology has signed a licensing agreement with an undisclosed drug UK firm for a chemotherapy drug, PIP-101.
Licensing 130
130 
TherapeuticsMD and Mayne sign product licensing agreements
Pharmaceutical Technology
DECEMBER 5, 2022
Women’s healthcare company TherapeuticsMD has sign ed agreements for licensing its products to the Mayne Pharma affiliate in the US. Additionally, TherapeuticsMD will grant Mayne the exclusive license to market Annovera in the US.
Licensing 130
130 
ERS Genomics and MDC sign CRISPR/Cas9 license agreement
Drug Discovery World
SEPTEMBER 5, 2024
ERS Genomics and not-for-profit Medicines Discovery Catapult (MDC) have signed a non-exclusive commercial-use CRISPR license agreement. Comprising 100+ patents globally, ERS’ portfolio encompasses CRISPR/Cas9 usage in all cells, including bacteria, archaea, yeasts, and algae, licensed via its direct license from Emmanuelle Charpentier.
Genome 52
52 
Tay Therapeutics and VYNE sign licensing deal for oral BET inhibitor
Pharmaceutical Technology
MAY 3, 2023
Tay Therapeutics, a spin-off firm from the University of Dundee in the UK, has signed a licensing deal with VYNE Therapeutics for the development of its oral bromodomain and extra-terminal domain (BET) inhibitor as a possible treatment for immune-inflammatory and fibrotic disorders.
Licensing 130
130 
Biogen licenses Denali’s amyloid beta programme for Alzheimer’s
Pharmaceutical Technology
APRIL 13, 2023
Biogen has exercised an option to license Denali Therapeutics ’ (Denali) programme to develop immunotherapies for the treatment of Alzheimer’s disease. We are pleased with Biogen’s decision to license ATV: Aβ and we are hopeful this will foster the development of next-generation anti-Aβ therapeutics.”
Licensing 130
130 
Let's personalize your content